In this test-specific episode of the "Answers From the Lab" podcast, Wei Shen, Ph.D., explains how Mayo Clinic Laboratories' new breast cancer panel provides rapid results to guide critical decisions about treatment and screening.
Sounak Gupta, M.B.B.S., Ph.D., explains how Mayo Clinic Laboratories' gynecological NGS panels provide focused assessments of gynecological cancers. The cost-effective tests fill the gap between single gene assays and large cancer panels, to inform prognosis and treatment.
Sounak Gupta, M.B.B.S., Ph.D., explains how Mayo Clinic Laboratories' urologic panels efficiently inform prognosis and individualized cancer treatment. The carefully curated panels fill the void between single gene assays and large NGS panels.
Molecular biomarkers are a critical component in the treatment of adult and pediatric brain tumors. Robert Jenkins, M.D., Ph.D., explains how Mayo Clinic Laboratories' chromosomal microarray provides more comprehensive and accurate tumor analysis compared with other test methods.
Cristiane (Cris) Ida, M.D., explains how Mayo Clinic Laboratories' updated neuro-oncology gene panel provides more clinically relevant information for managing adult and pediatric brain tumors.
Offering increased sensitivity and improved accuracy, MayoComplete next-generation testing ensures health care providers understand the distinctive genetic features of their patients’ cancer to make informed decisions to guide their care.
Gang Zheng, M.D., Ph.D., and Aaron Mansfield, M.D., describe Mayo Clinic Laboratories’ liquid biopsy, which analyzes blood samples for genetic information to guide cancer treatment. The circulating tumor DNA assay uses next generation sequencing and complements the laboratory's cell-based cancer testing.
William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, joins "Answers From the Lab" for his weekly leadership update with host Bobbi Pritt, M.D., interim chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic. In this episode, Dr. Pritt and Dr. Morice discuss their new roles at Mayo Clinic and update listeners on the latest legislative news impacting the laboratory and diagnostic industries. They also highlight the launch of MayoComplete, Mayo Clinic Laboratories’ robust suite of oncology and hematology testing that uses next-generation sequencing to identify and evaluate presence of mutations.
Rondell Graham, M.B.B.S., describes Mayo Clinic Laboratories' new assay for gastrointestinal stromal tumors, or GIST. The panel covers multiple mutations, to better inform diagnosis and treatment options.
In this month's "Hot Topic," Kevin Halling, M.D., Ph.D., discusses new next generation sequencing testing for various tumor types and the rationale for the enhancements that were made; reviews gene additions that are now available in each of the panels; and briefly speaks about the work that was done to validate cytology specimens for use in the subpanels.
In this test specific episode of the "Answers From the Lab" podcast, Ruifeng (Ray) Guo, M.D., Ph.D., explains how Mayo Clinic Laboratories' comprehensive melanoma panel better informs prognosis and treatment.
Rondell Graham, M.B.B.S., describes Mayo Clinic Laboratories' new colorectal cancer panel. The assay covers more genes to better inform decision-making about prognosis, targeted therapies and a hereditary cancer syndrome.
Ying-Chun Lo, M.D., Ph.D., explains how Mayo Clinic Laboratories' updated lung panel can better guide clinical decision-making, particularly about targeted lung cancer therapies.